The novel anti-CD40 monoclonal antibody CFZ533 shows beneficial effects in patients with primary sjögren's syndrome: A phase IIA double-blind, placebo-controlled randomized trial

This article has no abstract
Epistemonikos ID: c616a0c7d3dcc91563e232f755eed2dd4406d707
First added on: Feb 08, 2025